## Sara Massironi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8719736/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut, 2010, 59, 638-644.	6.1	358
2	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	6.3	345
3	Role of US in Detection of Crohn Disease: Meta-Analysis. Radiology, 2005, 236, 95-101.	3.6	279
4	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	1.8	279
5	Neuroendocrine tumors of the gastro-entero-pancreatic system. World Journal of Gastroenterology, 2008, 14, 5377.	1.4	152
6	Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. Clinical Nutrition, 2013, 32, 904-910.	2.3	126
7	Sporadic and MEN1-Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity. Journal of Bone and Mineral Research, 2009, 24, 1404-1410.	3.1	115
8	Plasma chromogranin a in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 867-871.	0.9	98
9	The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmunity Reviews, 2019, 18, 215-222.	2.5	94
10	Understanding short bowel syndrome: Current status and future perspectives. Digestive and Liver Disease, 2020, 52, 253-261.	0.4	82
11	The Role of Ultrasound Elasticity Imaging in Predicting Ileal Fibrosis in Crohn's Disease Patients. Inflammatory Bowel Diseases, 2015, 21, 2605-2612.	0.9	73
12	Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution. Neuroendocrinology, 2014, 100, 240-249.	1.2	72
13	Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation. Hepatology, 2010, 52, 1723-1730.	3.6	67
14	Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: A review. World Journal of Gastroenterology, 2017, 23, 563.	1.4	66
15	Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Digestive and Liver Disease, 2015, 47, 819-825.	0.4	64
16	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
17	Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. American Journal of Gastroenterology, 2010, 105, 2072-2078.	0.2	57
18	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology, 2018, 155, 479-489.e7.	0.6	54

#	Article	IF	CITATIONS
19	Neuroendocrine neoplasms of rectum: A management update. Cancer Treatment Reviews, 2018, 66, 45-55.	3.4	52
20	Primary sclerosing cholangitis associated with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2016, 28, 123-131.	0.8	51
21	Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. European Journal of Gastroenterology and Hepatology, 2010, 22, 180-184.	0.8	47
22	Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?. Scandinavian Journal of Gastroenterology, 2015, 50, 1397-1403.	0.6	45
23	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. Annals of Surgery, 2020, 271, 527-533.	2.1	44
24	Gastric carcinoids: Between underestimation and overtreatment. World Journal of Gastroenterology, 2009, 15, 2177.	1.4	43
25	Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. American Journal of Hematology, 2010, 85, 564-568.	2.0	40
26	Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Digestive and Liver Disease, 2018, 50, 6-14.	0.4	40
27	Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, 31-35.	0.4	39
28	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 2018, 25, 3200-3206.	0.7	39
29	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	1.8	38
30	Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms. Pancreas, 2018, 47, 1249-1255.	0.5	35
31	Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. Clinical Gastroenterology and Hepatology, 2020, 18, 2375-2377.	2.4	35
32	Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Digestive and Liver Disease, 2015, 47, 978-983.	0.4	33
33	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰⊉ cm: Study Protocol for a Prospective Observational Study. Frontiers in Medicine, 2020, 7, 598438.	1.2	33
34	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. Digestive and Liver Disease, 2019, 51, 1456-1460.	0.4	32
35	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 194-200.	1.8	32
36	Unusually aggressive type 1 gastric carcinoid. European Journal of Gastroenterology and Hepatology, 2012, 24, 589-593.	0.8	31

#	Article	IF	CITATIONS
37	Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. European Journal of Endocrinology, 2013, 168, 755-761.	1.9	30
38	Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey. Digestive and Liver Disease, 2021, 53, 682-688.	0.4	30
39	Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scandinavian Journal of Gastroenterology, 2018, 53, 835-842.	0.6	29
40	Therapy for metastatic pancreatic neuroendocrine tumors. Annals of Translational Medicine, 2014, 2, 8.	0.7	29
41	Endoscopic techniques to detect smallâ€bowel neuroendocrine tumors: A literature review. United European Gastroenterology Journal, 2017, 5, 5-12.	1.6	27
42	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist, 2020, 25, 259-265.	1.9	27
43	Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World Journal of Gastroenterology, 2005, 11, 7318.	1.4	27
44	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World Journal of Gastroenterology, 2021, 27, 5890-5907.	1.4	26
45	Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study. Journal of Clinical Medicine, 2019, 8, 1992.	1.0	25
46	Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Digestive and Liver Disease, 2010, 42, 635-641.	0.4	23
47	Chromogranin A and other enteroendocrine markers in inflammatory bowel disease. Neuropeptides, 2016, 58, 127-134.	0.9	23
48	Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scandinavian Journal of Gastroenterology, 2016, 51, 513-523.	0.6	22
49	Impact of Vitamin D on the Clinical Outcome of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Report on a Series from a Single Institute. Neuroendocrinology, 2017, 105, 403-411.	1.2	21
50	Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. World Journal of Gastroenterology, 2017, 23, 2640.	1.4	21
51	A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. Oncotarget, 2016, 7, 18978-18983.	0.8	21
52	Ultrasound elastographic techniques in focal liver lesions. World Journal of Gastroenterology, 2016, 22, 2647.	1.4	21
53	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290. 	2.8	21
54	Relevance of vitamin D deficiency in patients with chronic autoimmune atrophic gastritis: a prospective study. BMC Gastroenterology, 2018, 18, 172.	0.8	20

#	Article	IF	CITATIONS
55	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	1.6	18
56	Systematic review—pancreatic involvement in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1478-1491.	1.9	18
57	Response and relapse rates after treatment with longâ€acting somatostatin analogs in multifocal or recurrent typeâ€l gastric carcinoids: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2020, 8, 140-147.	1.6	17
58	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World Journal of Gastroenterology, 2022, 28, 1123-1138.	1.4	16
59	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	0.8	14
60	Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS ONE, 2018, 13, e0196858.	1.1	14
61	Somatostatin analogs for gastric carcinoids: For many, but not all. World Journal of Gastroenterology, 2015, 21, 6785-6793.	1.4	14
62	Treatment of Liver Metastases in Patients with Digestive Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2012, 16, 1981-1992.	0.9	13
63	Intraductal papillary mucinous neoplasms of the pancreas: a clinical challenge. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1123-1133.	1.4	13
64	Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. World Journal of Gastrointestinal Surgery, 2021, 13, 702-716.	0.8	13
65	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. World Journal of Gastroenterology, 2022, 28, 3258-3273.	1.4	13
66	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. Digestive and Liver Disease, 2017, 49, 978-983.	0.4	12
67	Small Bowel Ultrasound beyond Inflammatory Bowel Disease: An Updated Review of the Recent Literature. Ultrasound in Medicine and Biology, 2017, 43, 1741-1752.	0.7	12
68	Deficiency of micronutrients in patients affected by chronic atrophic autoimmune gastritis: A single-institution observational study. Digestive and Liver Disease, 2019, 51, 505-509.	0.4	12
69	The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. Journal of Clinical Medicine, 2022, 11, 3794.	1.0	12
70	Early effects of total paracentesis and albumin infusion on muscle sympathetic nerve activity in cirrhotic patients with tense ascites. Journal of Hepatology, 1999, 30, 95-100.	1.8	11
71	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World Journal of Gastroenterology, 2021, 27, 5520-5535.	1.4	10
72	Hepatic Hemangioma in Celiac Patients: Data from a Large Consecutive Series. Gastroenterology Research and Practice, 2015, 2015, 1-6.	0.7	9

#	Article	IF	CITATIONS
73	Clinical and Endoscopic Outcomes in COVID-19 Patients WithÂGastrointestinal Bleeding. , 2022, 1, 487-499.		9
74	Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. BMC Gastroenterology, 2014, 14, 110.	0.8	8
75	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. Inflammatory Bowel Diseases, 2020, 26, e138-e139.	0.9	8
76	Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study. Cells, 2022, 11, 692.	1.8	8
77	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. Pancreatology, 2018, 18, 792-798.	0.5	7
78	Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals, 2021, 14, 539.	1.7	7
79	An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: An unusual association and review of the literature. Journal of Cancer Research and Therapeutics, 2014, 10, 443.	0.3	6
80	IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. Endocrine, 2017, 58, 360-367.	1.1	6
81	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. Journal of Clinical Medicine, 2022, 11, 713.	1.0	6
82	Referrals for bowel ultrasound in clinical practice: A survey in 12 nationwide centres in Italy. Digestive and Liver Disease, 2011, 43, 165-168.	0.4	5
83	Effects of a Gluten-Containing Meal on Gastric Emptying and Gallbladder Contraction. Nutrients, 2018, 10, 910.	1.7	5
84	Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. Endocrine, 2022, 75, 942-948.	1.1	5
85	Transient elastography in patients with celiac disease: A noninvasive method to detect liver involvement associated with celiac disease. Scandinavian Journal of Gastroenterology, 2012, 47, 640-648.	0.6	4
86	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 18, 419-449.	0.6	4
87	A case of positive 68 Ga-DOTATOC-PET/CT pancreatic heterotopia mimicking an intestinal neuroendocrine tumor. Clinical Imaging, 2018, 49, 156-158.	0.8	3
88	Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?. Anticancer Research, 2014, 34, 7361-5.	0.5	3
89	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	1.0	3
90	"Pseudotumoral―hepatic pattern in acute alcoholic hepatitis: A case report. World Journal of Gastroenterology, 2009, 15, 4070.	1.4	1

#	Article	IF	CITATIONS
91	ASO Author Reflections: Heterogeneity of Duodenal Neuroendocrine Tumors. Annals of Surgical Oncology, 2018, 25, 858-859.	0.7	1
92	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. Scandinavian Journal of Gastroenterology, 2019, 54, 1111-1117.	0.6	1
93	Letter: pancreatic involvement in inflammatory bowel disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 371-371.	1.9	1
94	Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome. Gastroenterology, 2017, 152, S670.	0.6	0
95	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. Gastroenterology, 2017, 152, S669.	0.6	Ο
96	Reply. Pancreas, 2020, 49, e81-e82.	0.5	0
97	Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs). , 2021, , 55-74.		0